List view / Grid view
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
Researchers show that proteins released from the brain during migraine with aura are transported by CSF to pain-signalling nerves.
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
We had the privilege of speaking to Morgane Rousselot, co-founder and CEO of SeaBeLife for our Women in Stem series. With a strong scientific background and over two decades of entrepreneurial experience in the biotechnology field, she leads the company with a team-focused approach and intellectual rigor.
This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines. Its benefits mean it is poised to disrupt the $87 billion pain management market and…
